Endothelial changes in individuals with prehypertension

Current Hypertension Reviews

Volumn 12, Issue 2, 2016, Pages 134-138

  Valente, Flavia Mariana ^a   Vespasiano, Patricia ^b   Barbosa, Juliana Aparecida ^a   Cesarino, Claudia Bernardi ^a   Andrade, Days Oliveira De ^a   Fernandes, Leticia Aparecida Barufi ^a   Cosenso Martin, Luciana Neves ^a   Balduino Mendes, Alessandra Beatriz ^a   Gaglianone, Camila ^a   Vilela Martin, José Fernando ^c  

^a São José do Rio Preto Medical School FAMERP   (Brazil)

^b PAULISTA UNIVERSITY   (Brazil)

^c Professor of Medicine   (Brazil)

Author keywords

Prehypertension epidemiology etiology prevention control; Prevalence; Risk factors; Vascular endothelium

Indexed keywords

ANGIOTENSIN II; CALCIUM; ENDOTHELIN 1; ENDOTHELIUM DERIVED CONSTRICTING FACTOR; ENDOTHELIUM DERIVED RELAXING FACTOR; HEPARIN; KININ; NATRIURETIC FACTOR; NITRIC OXIDE SYNTHASE; PROSTACYCLIN; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE;

ARTICLE; ATHEROSCLEROSIS; BLOOD FLOW; BRAZIL; CALCIUM CELL LEVEL; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; HUMAN; HYPERTENSION; PREHYPERTENSION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VASCULAR ENDOTHELIUM; VASCULAR REMODELING; VASCULAR RESISTANCE; VASCULAR SMOOTH MUSCLE; VASODILATATION; CARDIOVASCULAR DISEASE; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR; VASOCONSTRICTION;

BRAZIL; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; HUMANS; PREHYPERTENSION; RISK FACTORS; VASOCONSTRICTION; VASODILATION;

EID: 84973621391     PISSN: 15734021     EISSN: 18756506     Source Type: Journal    
DOI: 10.2174/1573402111666150812143827     Document Type: Article

References (44)

1. Fuchs FD. Prehypertension: the rationale for early drug therapy.CardiovascTher 2010; 28: 339-43.
2. Martin JFV, Cipullo JP. Tratamento medicamentoso para a pré-hipertensão: para todos? Rev Bras Hipertens 2009; 16(1): 44-5.
3. Rosa MLG, Fonseca VM, Oigman G, et al. Pré-hipertensão arteriale pressão de pulso aumentada em adolescentes: prevalência e fatores associados. Arq Bras Cardiol 2006; 87(1): 46-53.
4. The Seventh Report of the Joint National Committee onPrevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003; 289(19): 2560-72.
5. Sanjuliani AF. Pré-hipertensão e risco cardiovascular global. RevBras Hipertens 2009; 16(2): 103-7.
6. Guo X, Zheng L, Zhang X, et al. The prevalence and heterogeneityof prehypertension: a meta-analysis and meta-regression of published literature worldwide. Cardiovasc J Afr 2012; 23(1): 44-50.
7. Pimenta E, Oparil S. Prehypertension: epidemiology, consequencesand treatment. Nat Rev Nephrol 2010; (6): 21-30.
8. Fergunson TS, Younges NOM, Tulloch-Reid MK, et al. Prevalenceof prehypertension and its relationship to risk factors for cardiovascular disease in Jamaica: analysis from a cross-sectional survey. BMC Cardiovasc Disord 2008; 8(20): 1-9.
9. Qureshi AI, Suri MFK, Kirmani JF, et al. Is prehypertension a riskfactor for cardiovascular diseases? Stroke 2005; 36: 1859-63.
10. Gu Q, Burt VL, Paulose-Ram R, et al. High blood pressure andcardiovascular disease mortality risk among U.S. adults: the third National Health and Nutrition Examination Survey mortality follow-up study. Ann Epidemiol 2008; 18(4): 302-9.
11. Zhang Y, Lee ET, Devereux RB, et al. Prehypertension, diabetesand cardiovascular disease risk in a population-based sample: The Strong Heart Study. Hypertension 2006; 47(3): 410-4.
12. Gupta P, Nagaraju SP, Gupta A, Mandya Chikkaingaiah KB. Prehypertension - time to act. Saudi J Kidney Dis Transpl 2012; 23(2): 223-33.
13. Egan BM, Stevens-Fabry S. Prehypertension - prevalence, healthrisks, and management strategies. Nat Rev Cardiol 2015; 2: 289-300.
14. Martin JFV, Martin LNC, Cipullo JP. Pharmacologic treatment forprehypertension: to treat or not to treat? Recent Pat Cardiovasc Drug Discov 2009; 4: 133-41.
15. Julius S, Nesbitt SD, Egan BM, et al. Feasibility of treatingprehypertension with an angiotensin-receptor blocker. N Engl J Med 2006; 354(16): 1685-97.
16. Svetkey LP. Management of prehypertension. Hypertension 2005;45: 1056-61.
17. Sasamura H, Itoh H, Julius S. Management or prehypertension:current status and future strategies. Curr Hypertens Rev 2011; 7(2): 118-24.
18. Glasser SP, Judd S, Basile J, et al. Prehypertension, racialprevalence and its association with risk factors: analysis of the reasons for geographic and racial differences in stroke (REGARDS) study. Am J Hypert 2011; 24(2): 194-9.
19. Ghisi GLM, Durieux A, Pinho R, et al. Exercício Físico eDisfunção Endotelial. Arq. Bras. Cardiol 2006; 95(5): 130-37.
20. Bahia L, Aguiar LGK, Villela NR, et al. O Endotélio na SíndromeMetabólica. Arq Bras Endocrino Metab 2006; 50(2): 291-303.
21. Zago AS, Zanesco A. Óxido Nítrico, Doenças Cardiovasculares eExercício Físico. Arq Bras Cardiol 2006; 87(6): 264-70.
22. Albarwani S, Al-Sivabi S, Tanira MO. Prehypertension:underlaying pathology and therapeutic options. World J Cardiol 2014; 6(8): 728-43.
23. Cosentino F, Patton S, d’Uscio LV, et al. Tetrahydrobiopterinalters superoxide and nitric oxide release in prehypertensive rats. J Clin Invest 1998; 101(7): 1530-7.
24. Neves MF, Kasal DA, Cunha AR, et al. Vascular dysfunction astarget organ damage in animal models of hypertension. Int J Hypertens 2012; 2012: 187526.
25. Guimarães DA, Rizzi E, Ceron CS, et al. Inibição demetaloproteinases da matriz extracelular: uma possível estratégia terapêutica na hipertensão arterial? Rev Bras Hipertens 2010; 17(4): 226-30.
26. Duprez DA, Hearst MO, Lutsev PL, et al. Associations among lungfunction, arterial elasticity, and circulating endotelial and inflammation markers. Hypertension 2013; 61: 542-48.
27. Melo S, Toledo JCY, Coca AP, et al. Hipertensão arterial,aterosclerose e inflamação: o endotélio como orgão-alvo. Rev Bras Hipertens 2007; 14(4): 234-38.
28. Ghasemi A, Zahediasl S, Syedmoradi L, et al. Association betweenserum nitric oxide metabolites and hypertension in general population. Int Angiol 2011; 30(4): 380-7.
29. Wang Z, Liu Y, Liu J, et al. A pilot study on level of bloodvasoactive factors in prehypertensive and hypertensive patients. Clin Exp Hypertens 2008; 30(7): 598-605.
30. Taddei S, Virdis A, Ghiadoni L, et al. Role of endothelin in thecontrol of peripheral vascular tone in human hypertension. Heart Fail Rev 2001; 6(4): 277-85.
31. Hynynen MM, Khalil RA. The vascular endothelin system inhypertension - recent patents and discoveries. Recent Pat Cardiovasc Drug Discov 2006; 1(1): 95-108.
32. Schiffrin EL. Vascular endothelin in hypertension. VasculPharmacol 2005; 43(1): 19-29.
33. Pinto-Sietsma SJ, Paul M. A role for endothelin in the pathogenesisof hypertension: fact or ficton? Kidney Int Suppl 1998; 67: 115-21.
34. Mazzuca MQ, Khalil RA. Vascular endothelin receptor type B:structure, function and dysregulation in vascular disease. Biochem Pharmacol 2012; 84(2): 147-62.
35. Weil BR, Westby CM, Greiner JJ, et al. Elevated endothelin-1vasoconstrictor tone in prehypertensive adults. Can J Cardiol 2012; 28(3):347-353
36. Feairheller DL, Sturgeon KM, Diaz KM, et al. PrehypertensiveAfrican-American women have preserved nitric oxide and renal function but high cardiovascular risk. Kidney Blood Press Res 2010; 33: 282-90.
37. Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases:structure, function and inhibition. Biochem J 2001; 357: 593-615.
38. Félétou M, Köhler R, Vanhoutte PM. Endothelium-derivedvasoactive factors and hypertension: possible roles in pathogenesis and as treatment targets. Curr Hypertens Rep 2010; 12: 267-75.
39. Weil BR, Stauffer BL, Greiner JJ, et al. Prehypertension isassociated with impaired nitric-oxide-mediated endothelium-dependent vasodilatation in sedentary adults. Am J Hypertens 2011; 24(9): 976-81.
40. Diehl KJ, Weil BR, Greiner JJ, et al. Impaired endogenousfibrinolytic capacity in prehypertensive men. J Hum Hypertens 2015; 29(8): 468-72.
41. Van Guilder GP. It is time to contend with the endothelialconsequences of prehypertension. J Human Hypertens 2015; 1-2.
42. Guo X, Zou L, Zhang X, et al. Prehypertension: Meta-Analysis ofthe Epidemiology, RiskFactors, and Predictors of Progression. Tex Heart Inst J 2011; 38(6): 643-52.
43. Duprez D, Toleuova A. Prehypertension and the cardiometabolicsyndrome. Expert Rev Cardiovasc Ther 2013; 11(12): 1725-33.
44. Kalaitzidis RG, Bakris GL. Prehypertension: is it relevant for nephrologists? Kidney Int 2010; 77(3): 194-200.